Lymphoma

Bristol-Myers Squibb's Breyanzi Aces Two Lymphoma Studies On Overall Response Rate Endpoint, Plus New Collaboration

Fate Therapeutics Showcases Interim Data From FT596 Cell Program In Lymphoma

Gilead's CAR-T Yescarta Shows 78% Complete Response Rate In First-Line Lymphoma Patients

Fate Therapeutics Showcases Interim Data From FT596 Cell Program In Lymphoma

Gilead's CAR-T Yescarta Shows 78% Complete Response Rate In First-Line Lymphoma Patients

Viracta Therapeutics Posts Data From Lymphoma Trial At ASH Presentation

Jazz Posts New Data for ALL/LBL Treatment At ASH 2021 Annual Meeting

Viracta Therapeutics Posts Data From Lymphoma Trial At ASH Presentation

Jazz Posts New Data for ALL/LBL Treatment At ASH 2021 Annual Meeting

Roche Uncorks Favorable Responses From Mosunetuzumab In Follicular Lymphoma Settings

Gilead's Kite Unveils More Data On Yescarta In Second-Line Lymphoma Patients

Lymphoma Recent News

Bristol Myers Reveals Full Data For Breyanzi In Second-Line Lymphoma Setting

Bristol Myers Squibb & Co (NYSE: BMY)

TG Therapeutics Shares Plunge After FDA Plans AdComm Meet For Blood Cancer Candidate

TG Therapeutics Inc (NASDAQ: TGTX) shares are falling after FDA notified the Company that it plans to host an Oncologic Drugs Advisory Committee (ODAC) meeting for marketing application regarding ublituximab/ Ukoniq (umbralisib) (U2 combo).

Affimed's Lymphoma Candidate Shows 100% Objective Response Rate At Highest Dose

Affimed NV (NASDAQ: AFMD) has announced

Soligenix To File US Application For Its Lymphoma Photodynamic Therapy In 2H 2022

Gilead's Kite Files US Application To Expand Use Of Yescarta In Second-Line Setting

BeiGene's Brukinsa Scores FDA Approval For Marginal Zone Lymphoma

Soligenix Stock Moves Higher On US Orphan Drug Tag For T-cell Lymphoma Candidate

ADC Therapeutics Announces $325M Financing Agreement With HealthCare Royalty

Fate Therapeutics' Stem Cell-Derived NK Lymphoma Candidate Casts Doubt Over Durability Of Response

Cellectar Receives $2M NIH Grant For Rare Lymphoma Study

F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients

BeiGene's Brukinsa Scores Second Approval In Canada, This Time For Mantle Cell Lymphoma

Fate Therapeutics Stock is Trading Higher on Positive B-Cell Lymphoma Data at ASCO21

Precision BioSciences' CD-19 CAR T Therapy Shows Response Rate Of 77% In Lymphoma Trial

BeiGene's Brukinsa US Application For Expanded Use Under FDA Review

Soligenix Stock Plummets After It Announces Not To Pursue Rolling US Application Submission For HyBryte

ADC Therapeutics Stock Jumps On Scoring First FDA Approval For DLBCL Treatment

Affimed Stock Jumps After Natural Killer Cells With AFM13 Show Clinical Responses, Minimal Toxicity

IMV's Lead Candidate To Be Evaluated With Keytruda In Pretreated B-Cell Lymphoma Patients

Affimed To Continue Enrollment In AFM13 Lymphoma Study After Positive Interim Data

Following the Independent Review Committee's assessment, Affimed NV (NASDAQ: AFMD)

BeiGene's US Application For BRUKINSA In A Type Of Lymphoma, Accepted For Review

Miragen Could Surpass $1 Billion In Revenue In 2025, Says Biotech Analyst

Here's Why Seattle Genetics' Adcetris Is A $2 Billion Product